MedPath

Paroxetine

Generic Name
Paroxetine
Brand Names
Paxil, Pexeva
Drug Type
Small Molecule
Chemical Formula
C19H20FNO3
CAS Number
61869-08-7
Unique Ingredient Identifier
41VRH5220H
Background

Paroxetine is a selective serotonin reuptake inhibitor (SSRI) drug commonly known as Paxil. It has a variety of uses, including the treatment of anxiety disorders, major depression, posttraumatic stress disorder, and symptoms of menopause, among others. It was approved by the FDA in the early 1990s and marketed by SmithKline Beecham. A unique feature of this drug is that it is highly potent and selective in its inhibition of serotonin reuptake and has little effect on other neurotransmitters. Because of its potent inhibition of serotonin reuptake, paroxetine is more likely to cause withdrawal effects upon cessation. Paroxetine is well tolerated in most patients with a similar adverse effect profile to other members of its drug class. The controlled release formulation was designed to decrease the likelihood of nausea that is sometimes associated with paroxetine.

Indication

Paroxetine is indicated for the management of depression, obsessive-compulsive disorder, panic disorder, social anxiety disorder, generalized anxiety disorder, posttraumatic stress disorder. One form of paroxetine, commercially known as Brisdelle, is used to manage mild to moderate vasomotor symptoms of menopause. Off-label, paroxetine may be used for the treatment of premature ejaculation or irritable bowel syndrome (IBS).

Associated Conditions
Generalized Anxiety Disorder, Irritable Bowel Syndrome (IBS), Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD), Panic Disorder, Post Traumatic Stress Disorder (PTSD), Premature Ejaculation, Premenstrual Dysphoric Disorder (PMDD), Social Anxiety Disorder (SAD), Vasomotor Symptoms Associated With Menopause

Paroxetine-mediated GRK2 Inhibition to Reduce Cardiac Remodeling After Acute Myocardial Infarction

Phase 2
Completed
Conditions
Myocardial Infarction
Cardiac Remodeling
Interventions
Drug: Placebo oral capsule
First Posted Date
2017-09-07
Last Posted Date
2022-06-01
Lead Sponsor
Insel Gruppe AG, University Hospital Bern
Target Recruit Count
50
Registration Number
NCT03274752
Locations
🇨🇭

Bern University Hospital, Department of Cardiology, Bern, Switzerland

Hot Flash as a Marker of Cardiovascular Risk in Recent Postmenopause: Effects of Non-hormonal Treatments

Phase 4
Completed
Conditions
Postmenopausal Flushing
Endothelial Dysfunction
Cardiovascular Risk Factor
Interventions
Drug: Placebo oral capsule
First Posted Date
2017-05-11
Last Posted Date
2018-04-12
Lead Sponsor
Rio de Janeiro State University
Target Recruit Count
140
Registration Number
NCT03149419
Locations
🇧🇷

Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil

Impact of Genetic Polymorphism on Drug-Drug Interactions Involving CYP2D6

First Posted Date
2017-02-15
Last Posted Date
2019-04-19
Lead Sponsor
Jules Desmeules
Target Recruit Count
34
Registration Number
NCT03054220

Effect of Vortioxetine, Paroxetine, and Placebo on Sexual Functioning in Healthy Volunteers

Phase 4
Completed
Conditions
Healthy Volunteers
Interventions
First Posted Date
2016-10-13
Last Posted Date
2018-09-14
Lead Sponsor
Takeda
Target Recruit Count
361
Registration Number
NCT02932904

Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies

Terminated
Conditions
Bipolar Disorder
First Posted Date
2016-09-08
Last Posted Date
2024-03-12
Lead Sponsor
University of New Mexico
Target Recruit Count
1037352
Registration Number
NCT02893371
Locations
🇺🇸

Christophe G Lambert, Albuquerque, New Mexico, United States

Long Term Treatment of Panic Disorder With Clonazepam or Paroxetine

Phase 4
Completed
Conditions
Agoraphobia
Panic Disorder
Interventions
First Posted Date
2016-08-02
Last Posted Date
2016-08-02
Lead Sponsor
Universidade Federal do Rio de Janeiro
Target Recruit Count
120
Registration Number
NCT02852577
Locations
🇧🇷

Instituto de Psiquiatria da Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil

Lofexidine Pharmacokinetics in the Presence of Paroxetine in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2016-02-12
Last Posted Date
2018-02-23
Lead Sponsor
USWM, LLC (dba US WorldMeds)
Target Recruit Count
24
Registration Number
NCT02681198
Locations
🇺🇸

Worldwide Clinical Trials, San Antonio, Texas, United States

A Policy Relevant US Trauma Care System Pragmatic Trial for PTSD and Comorbidity

Not Applicable
Completed
Conditions
Depression
Posttraumatic Stress Disorder
Mild Cognitive Impairment
Alcohol-Related Disorders
Substance-Related Disorders
Wounds and Injury
Suicidal Ideation
Brain Injuries
Quality of Life
Chronic Disease
Interventions
First Posted Date
2016-01-14
Last Posted Date
2021-07-02
Lead Sponsor
University of Washington
Target Recruit Count
635
Registration Number
NCT02655354
Locations
🇺🇸

Jacobi Medical Center, Bronx, New York, United States

🇺🇸

University of Rochester, Rochester, New York, United States

🇺🇸

Honor Health, Scottsdale, Arizona, United States

and more 21 locations

Newer Antidepressants in Combination With Pregabalin for Fibromyalgia Syndrome

Phase 1
Completed
Conditions
Fibromyalgia
Interventions
First Posted Date
2015-05-22
Last Posted Date
2015-05-22
Lead Sponsor
Mansoura University
Target Recruit Count
75
Registration Number
NCT02451475

Pharmacovigilance in Gerontopsychiatric Patients

Phase 3
Terminated
Conditions
Dementia
Depression
Schizophrenia
Psychosomatic Disorders
Anxiety Disorders
Interventions
First Posted Date
2015-03-02
Last Posted Date
2018-02-28
Lead Sponsor
Hannover Medical School
Target Recruit Count
407
Registration Number
NCT02374567
Locations
🇩🇪

Bezirkskrankenhaus Augsburg, Augsburg, Germany

🇩🇪

Krankenhaus Hedwigshöhe, Berlin, Germany

🇩🇪

Hannover Medical School, Hannover, Germany

and more 2 locations
© Copyright 2025. All Rights Reserved by MedPath